Viatris Q3 FY25: where the revenue came from and where it went
The income statement of Viatris for this quarter, down to the operating result, as one diagram: what earned the revenue and what it went on. The bottom line is withheld; the note under the table says why.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 6, 2025
Revenue$3.76B
+0% year over year
Gross profit$1.37B
36% margin
Operating profit$0.18B
5% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.76 | 100% | +0% |
| Brands | 2.44 | 65% | +3% |
| Lipitor | 0.40 | 11% | +5% |
| Other revenue | 0.35 | 9% | |
| Epi pen auto injectors | 0.16 | 4% | +28% |
| Lyrica | 0.13 | 3% | −3% |
| Influvac | 0.13 | 3% | +3% |
| Creon | 0.09 | 3% | +10% |
| Celebrex | 0.07 | 2% | −1% |
| Cost of revenue | −2.39 | 64% | |
| Gross profit | 1.37 | 36% margin | −2pp |
| R&D | −0.25 | 7% | +1pp |
| SG&A | −0.89 | 24% | −3pp |
| Other | −0.06 | 1% | +0pp |
| Operating profit | 0.18 | 5% margin | −1pp |
95 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest